Theorem Clinical Research

Global News

Online advertising is becoming more prevalent, successful in targeting patient populations

Monday, August 25, 2014 06:00 AM

Technology advances in clinical trials are changing how we manage patient recruitment.

More... »


Initiative for emergency Ebola research formed by Wellcome Trust, U.K. government

Friday, August 22, 2014 11:59 AM

A $10.8 million emergency funding package for research to contain the Ebola epidemic in West Africa and future outbreaks of infectious disease has been initiated by the U.K-based Wellcome Trust and the U.K. Department for International Development, administered by Enhancing Learning and Research for Humanitarian Assistance (ELRHA).

More... »


ViaCyte, Janssen R&D ink agreement

Friday, August 22, 2014 11:54 AM

ViaCyte, a San Diego-based, privately held regenerative medicine company, has entered into a $20 million rights agreement with Janssen R&D, a unit of Johnson & Johnson. The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01 combination product that ViaCyte is developing for type 1 diabetes. This right will continue through the initial evaluation of clinical efficacy of VC-01. 

More... »

Report: Dengue vaccine market to experience rapid growth from 2015 to 2020

Friday, August 22, 2014 11:53 AM

Among the five pharmaceutical markets of Brazil, India, Mexico, Singapore and Thailand, Brazil and Mexico are projected to be the leading contributors to the dengue vaccine marketplace, as it expands rapidly from an estimated $70 million in 2015 to $400 million by 2020, at a Compound Annual Growth Rate (CAGR) of 42%, according to U.K. research and consulting firm GlobalData.

More... »

Emergent BioSolutions, MorphoSys ink agreement for ES414

Friday, August 22, 2014 11:52 AM

Emergent BioSolutions, a Rockville, Md.-based global specialty biopharmaceutical company, and MorphoSys, a Germany-based provider of therapeutic antibodies, have inked an agreement for the joint development and commercialization of Emergent’s preclinical bi-specific antibody, ES414, targeting prostate cancer. Emergent will receive an upfront payment of $20 million and milestone payments of up to $163 million.

More... »

Novartis provides drug candidate compounds to TB Alliance

Thursday, August 21, 2014 01:48 PM

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance), which has locations in the U.S., Brussels and South Africa, for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).

More... »

AstraZeneca, Mitsubishi Tanabe Pharma collaborate on diabetic nephropathy

Thursday, August 21, 2014 01:45 PM

AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC), a research-driven pharmaceutical company based in Japan, have announced a three-year research collaboration in diabetic nephropathy. The aim is to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development.

More... »

Bristol-Myers Squibb, Celgene collaborate on combination regimen

Thursday, August 21, 2014 01:44 PM

Bristol-Myers Squibb and Celgene have established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of BMS’ investigational PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), and Celgene’s nab technology-based chemotherapy Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), in a phase I study.

More... »

Illumina partners with AstraZeneca, Janssen, Sanofi for oncology

Thursday, August 21, 2014 01:42 PM

Illumina, a California-based developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function, has formed collaborative partnerships with AstraZenecaJanssen Biotech and Sanofi to develop a universal next-generation sequencing (NGS)-based oncology test system.

More... »

Positive results released for Amgen’s phase III study of AMG 416

Thursday, August 21, 2014 10:24 AM

Amgen has announced that a second placebo-controlled, phase III study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs